SCHEMBL6500299

SCHEMBL6500299

CN1CC2CC1CN2c1cc[c]c(C(=O)NCC2C3CN(C(=O)c4ccc(C(C)(C)C)cc4)CC23)n1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.34
ALOX15 P16050 1/20 0.34
SMN1; SMN2 Q16637 5/20 0.33
ALDH1A1 P00352 4/20 0.33
MAPK1 P28482 2/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
HSD11B1 P28845 1/20 0.33
POLB P06746 1/20 0.33
RAB9A P51151 1/20 0.33
HTT P42858 2/20 0.32
TYK2 P29597 2/20 0.32
NPY5R Q15761 2/20 0.32
CRHBP P24387 1/20 0.32
CRHR2 Q13324 1/20 0.32
PARP1 P09874 1/20 0.32
LMNA P02545 3/20 0.32
THRB P10828 1/20 0.32
CACNA1H O95180 1/20 0.32
MAPT P10636 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4419305 0.85 SMN1; SMN2 (0.35) HPGDALOX15SMN1; SMN2ALDH1A1MAPK1
SCHEMBL4415706 0.84 HPGD (0.44) HPGDALOX15SMN1; SMN2ALDH1A1MAPK1
SCHEMBL4415367 0.82 CACNA1H (0.38) HPGDALOX15SMN1; SMN2ALDH1A1MAPK1
SCHEMBL4413362 0.82 GAA (0.43) SMN1; SMN2ALDH1A1POLBRAB9AHTT
SCHEMBL4414867 0.82 GBA1 (0.36) HPGDALOX15SMN1; SMN2ALDH1A1MAPK1
SCHEMBL4421392 0.82 HPGD (0.41) HPGDALOX15SMN1; SMN2ALDH1A1MAPK1
SCHEMBL4423656 0.80 BTK (0.39) SMN1; SMN2ALDH1A1POLBRAB9AHTT
SCHEMBL4418097 0.80 HRH3 (0.39) SMN1; SMN2ALDH1A1MAPK1MEN1KMT2A
SCHEMBL4425062 0.79 TSHR (0.36) SMN1; SMN2ALDH1A1MAPK1MEN1KMT2A
SCHEMBL4424740 0.79 HPGDS (0.37) HPGDALOX15SMN1; SMN2ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 HPGD 2537/4885ALOX15 3524/4885SMN1; SMN2 4003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.